Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Ȩ > ±Û·Î¹ú ÆÄÆ®³Ê > I > Insight Pharma Reports
Áö¿ª
Ä«Å×°í¸®·Î ã±â
ÆÄ¸Ó½´Æ¼ÄÃ

Insight Pharma Reports

Insight Pharma Reports¸¦ ¹ßÇàÇÏ´Â Cambridge Healthtech Institute(CHI)´Â ÁÖ¿ä Á¦¾à±â¾÷, ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷, Çмú±â°üÀÇ Àü¹®°¡¿Í ¿¬±¸¿øµé À§ÇÑ »ý¸í°úÇÐ ³×Æ®¿öÅ©¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. CHI´Â °¢Á¾ »ý¸í°úÇÐ ÄÁÆÛ·±½º ÁÖÃÖ¸¦ ºñ·ÔÇØ, ½Å·ÚÇÒ¸¸ÇÑ Á¤º¸¿Í ½Éµµ ±íÀº ºÐ¼®À» Á¦°øÇÏ´Â º¸°í¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç ¶ÇÇÑ ´Ù¾çÇÑ e-´º½º·¹ÅÍ ¹× BIO-IT World MagazineÀ» ¹ß°£Çϰí ÄÁ¼³ÆÃ, ±³À°¼­ºñ½º, ¸¶ÄÉÆÃ ¼­ºñ½º µîÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

»ó¼¼ ºÐ·ù
Á¦¸ñ °Ë»ö
1 - 25 ¸®ºä (Àüü£º 90 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
Backup Compound Strategies: Commercial and Tactical Considerations
»ùÇÃ
»óǰÄÚµå :238168
ÀǾàǰ »ç¾÷üÀÇ ¹é¾÷ È­ÇÕ¹°(Backup Compound) °ü·Ã °¢Á¾ Àü·«¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, ¹é¾÷ È­ÇÕ¹°ÀÇ Á¤ÀÇ, ¹é¾÷ È­ÇÕ¹° À̿뿡 °üÇÑ °ú°Å »ç·Ê, ÇöÀç ½ÃÇàµÇ°í ÀÖ´Â ¹é¾÷ Àü·«, ¹é¾÷ È­ÇÕ¹°ÀÇ ¼³°è¡¤¼±Á¤¡¤À¯¿ë¼º¿¡ °üÇÑ °ËÁõ, ºñÁö´Ï½º °ü·Ã °ËÅä»çÇ×, Àü¹®°¡ ÀÎÅÍºä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,495
¹ßÇàÀÏ 2012³â 04¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Fragment-Based Drug Discovery: Technologies, Applications, and Pipelines
»ùÇÃ
»óǰÄÚµå :237078
FBDD(Fragment-Based Drug Discovery) ±â¼ú¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, È­Çп¡ °üÇÑ ºÐ¼®°ú ÇÁ·¡±×¸ÕÆ® ÀÌ¿ëÀÇ ÀÌÁ¡, ½ºÅ©¸®´× ¾îÇÁ·ÎÄ¡ Á¾·ù¿Í °¢°¢ÀÇ ÀÌÁ¡°ú ´ÜÁ¡, ÁÖ¿ä »ç¾÷ÀÚÀÇ ÇÁ·¡±×¸ÕÆ® ±â¹Ý ÀǾàǰ ¼³°è »ç·Ê ¿¬±¸, ÀÓ»ó °³¹ß ´Ü°è È­ÇÕ¹° ¸®ºä, ÁÖ¿ä ±â¾÷ °³¿ä, Á¶»ç °á°ú µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 795
¹ßÇàÀÏ 2012³â 04¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Hematological Cancer Therapies: Pipelines, Markets, and Business Considerations - Overview
»ùÇÃ
»óǰÄÚµå :232489
Ç÷¾×¾Ï(Hematological Cancer) Ä¡·áÁ¦ Á¦Ç° ¹× ÆÄÀÌÇÁ¶óÀÎ µ¿Çâ, »ç¾÷ °úÁ¦¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ´Ù¾çÇÑ Ç÷¾×¾Ï Á¾·ù¿Í °³¿ä, ÇöÀç Ä¡·á¹ý, »õ·Î¿î Ä¡·áÁ¦ °³¹ß µ¿Çâ, ÇöÀç ½ÃÀå Æò°¡¿Í »õ·Î¿î Ä¡·áÁ¦ ½ÃÀå ÀáÀ缺 ºÐ¼®, ÀǾàǰ »ç¾÷ÀÚÀÇ °úÁ¦, Àü¹®°¡ÀÇ °ßÇØ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,495
¹ßÇàÀÏ 2012³â 02¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
High-Content Analysis: Technologies, Applications, and Market Dynamics
»ùÇÃ
»óǰÄÚµå :228355
ÇÏÀÌÄÁÅÙÆ® ºÐ¼®(HCA : High-Content Analysis) ±â¼ú, ¿ëµµ, ½ÃÀå ¹ßÀü »óȲ¸¦ Á¶»ç ºÐ¼®Çϰí, HTS ¹× HCS·ÎºÎÅÍÀÇ ¹ßÀü »óȲ, HCA ½ÇÇö ±â¼ú°ú ÇöÀç À̿밡´ÉÇÑ ½Ã½ºÅÛ °³¿ä, HCA ÀÌ¿ë ºÐ¾ß¿Í ¿ëµµ, °æÀï ±¸µµ°ú ÁÖ¿ä °Å·¡/°è¾à ºÐ¼®, HCA »ç¿ëÀÚÀÇ ÀÌ¿ë µ¿Çâ Á¶»ç, Àü¹®°¡ ÀÎÅÍºä µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,795
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
The PI3K/Akt/mTOR Pathway: A Pipeline Analysis - Overview
»ùÇÃ
»óǰÄÚµå :224231
PI3K, Akt, mTOR ÀúÇØÁ¦ ¹× ¸ÖƼŰ³ª¾ÆÁ¦ ÀúÇØÁ¦ °³¹ß »óȲÀ» Á¶»ç ºÐ¼®Çϰí, °¢°¢ÀÇ Ä¡·áÀû °³ÀÔ°ú Ä¡·á Àü·«, PI3K, Akt, mTOR °¢ ÀúÇØÁ¦, ÀÌÁß ÀúÇØÁ¦ °³¹ß »óȲ, ÁÖ¿ä ±â¾÷ Ȱµ¿, Àü¹®°¡ ÀÎÅÍºä µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,495
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
New Trends in Preventive and Therapeutic Vaccines - Overview
»ùÇÃ
»óǰÄÚµå :223064
¹é½Å(Vaccines) ¾÷°èÀÇ ÇöȲ°ú ¹ßÀü µ¿Çâ, 2020³â±îÁöÀÇ Àü¸Á µîÀ» ¹é½Å ºñÁö´Ï½º¿¡ ÁøÃâÇÑ ´ëÇü Á¦¾àȸ»ç ¹× ¼Ò±Ô¸ð Àü¹® ±â¾÷ °³¿ä¿Í ÇÔ²² ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,495
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Cytokine-Based Therapies and Inhibitors: R&D Pipelines, Markets, and Strategic Issues - Overview
»ùÇÃ
»óǰÄÚµå :214220
Ãâ½ÃµÇ°í ÀÖ´Â »çÀÌÅäÄ«ÀÎ ¿ä¹ý°ú ÀúÇØÁ¦(Cytokine-Based Therapies and Inhibitors) °³¿ä, ½ÅÈï Ä¡·á¹ý, °³¹ß ÆÄÀÌÇÁ¶óÀΰú Ç¥ÀûÀ¸·Î ÇÏ´Â ÀûÀÀ, ÀÓ»ó µ¥ÀÌÅÍ, ½ÃÀå ÇöȲ, ¸ÅÃâ µ¥ÀÌÅÍ, ÇØ°áÇØ¾ß ÇÒ °úÁ¦ µîÀÇ ½ÃÀå µ¿ÇâÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,495
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Kinase-Targeted Therapeutics: Development Pipelines, Challenges, and Opportunities
»ùÇÃ
»óǰÄÚµå :210216
Ű³ª¾ÆÁ¦(Kinase)¸¦ Ç¥ÀûÀ¸·Î ÇÑ Ä¡·áÁ¦ °³¹ß µ¿Çâ, È­ÇÕ¹° °³¹ß¿¡ ÀÀ¿ëµÇ´Â ÇöÀç ±â¼ú ¹× ½ÅÈï ±â¼ú, Ű³ª¾ÆÁ¦ Á¶Àý¿¡ ´ëÇØ ¿¬±¸ÁßÀÎ ÁÖ¿ä ±â¾÷°ú ±× ÇÁ·ÎÁ§Æ®, ´Ù¾çÇÑ Å°³ª¾ÆÁ¦ Ŭ·¡½ºÀÇ Æ¯Â¡, ¾÷°è°¡ Á÷¸éÇÑ °úÁ¦, ÇöÀç µ¿Ç⠵ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Engineering Next-Generation Therapeutic Proteins: Trends and Markets To 2020 - Overview
»ùÇÃ
»óǰÄÚµå :207708
Ä¡·á¿ë ´Ü¹éÁú(Therapeutic Proteins) °øÇп¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ÇöÀçÀÇ ±â¼ú µ¿Çâ°ú 2020³â±îÁöÀÇ ¹ßÀü µ¿Çâ, ½ÃÀå ÁøÃâ±â¾÷ 60»ç °³¿ä, ÇâÈÄÀÇ ºñÁö´Ï½º ¹æÇ⼺ µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö 214 Pages
Next-Generation Mass Spectrometry: Technology Advances and Applications - Overview
»ùÇÃ
»óǰÄÚµå :208331
Áú·®ºÐ¼®(Mass Spectrometry)ÀÇ °³¿ä, °Ô³ë¹Í½º, ÇÁ·ÎÅ׿À¹Í½º, ¸ÞŸº¼·Î¹Í½º µî¿¡¼­ Áú·®ºÐ¼®ÀÇ ¿ªÇÒ, ÇöÀçÀÇ ±â¼úÀû ¹ßÀü, »õ·Î¿î ÀÀ¿ë ºÐ¾ß, ÇâÈÄ Àü¸Á µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances
»ùÇÃ
»óǰÄÚµå :199300
Â÷¼¼´ë ½ÃÄö½Ì ½Ã½ºÅÛÀÇ °³¿ä ¹× °³¹ßÁßÀÎ ±â¼úÇõ½Å µ¿Çâ, Àåºñ ¹× ¼­ºñ½º µ¿Çâ, 6¸íÀÇ Àü¹®°¡ ÀÎÅͺä, ÇâÈÄ ¹ßÀü ¿¹Ãø µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Multitargeted Therapies: Promiscuous Drugs and Combination Therapies
»ùÇÃ
»óǰÄÚµå :199299
º¹ÇÕÇ¥Àû¿ä¹ý(Multitargeted Therapies)ÀÇ °³¹ß¿¡ À־ÀÇ ´Ù¾çÇÑ Á¢±Ù¹ý¿¡ ÃÊÁ¡À» ¸ÂÃß¾úÀ¸¸ç, º¹ÇÕÇ¥Àû¿ä¹ýÀÇ °³¿ä¿Í ½Å±Ô ³×Æ®¿öÅ© ¾à¸®ÇÐ ºÐ¾ß, Ä¡·á¿¡ ´ëÇÑ ³»¼ºÀ» ±Øº¹Çϱâ À§ÇÑ Á¦2¼¼´ë ¾àÁ¦ °³¹ß µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Commercializing Biomarkers in Therapeutic and Diagnostic Applications
»ùÇÃ
»óǰÄÚµå :199295
¹ÙÀÌ¿À¸¶Ä¿ÀÇ °³¿ä, ¾Ï, ½ÉÀå, ½Å°æ°ú, ¾à¹°¾ÈÀü¼º µîÀÇ ºÐ¾ß¿¡¼­ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ÀÀ¿ë µ¿Çâ, ½ÃÀå ÁøÃâ ±â¾÷ÀÇ °³¿ä, Ä¡·á ¹× Áø´Ü¿ë ¹ÙÀÌ¿À¸¶Ä¿ÀÇ »óǰȭ Àü·« µî¿¡ ´ëÇØ Àü¹®°¡ÀÇ ÀÎÅͺ並 Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2011³â 05¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Monoclonal Antibodies in the Pipeline: A Segment of Major Growth Report
»ùÇÃ
»óǰÄÚµå :175260
ÀÓ»ó °³¹ß ÁßÀÎ ¸ð³ëÅ©·Î³Î Ç×ü¸¦ °ËÁõÇϰí Ãâ½Ã Ç×üÀÇ ¸ÅÃâ, ±â¾÷ÀÇ ½ÃÀå Á¡À¯À², »óȯ°ú ¹ÙÀÌ¿À½Ã¹Ð·¯ µîÀÇ À§Çù, ÁøÃâ ±â¾÷ °³¿ä µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2011³â 03¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö 173 Pages
Molecular Diagnostics: Double-Digit Growth Anticipated Report
»ùÇÃ
»óǰÄÚµå :175259
ºÐÀÚ Áø´ÜÀ» µÑ·¯½Ñ ±â¼ú °³¿ä, ÇöÀç ½ÃÀåÀÇ Á¦Ç°°ú ½Ã½ºÅÛ, °³¹ß ÁßÀÎ Á¦Ç°°ú ½Ã½ºÅÛ, °æÀï µ¿Çâ, ±ÔÁ¦ °³¿ä, ÁøÃâ ±â¾÷ °³¿ä µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2011³â 02¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö 125 Pages
Advanced Drug Delivery Technologies: Enabling Drug Reformulations and Administration Routes Report
»ùÇÃ
»óǰÄÚµå :175258
¾à¹°Àü´Þ(Drug Delivery) ±â¼ú¿¡¼­ ÀÇ·á±â±âÀÇ ¿ªÇÒ, ³ª³ëÅ×Å©³î·¯ÁöÀÇ ÀÀ¿ë, ¾à¹°Àü´Þ¿¡ ÀÇÇÑ »ý¹°ÇÐÀû À庮ÀÇ ±Øº¹, ´ëüÀû Åõ¿© ¹æ¹ý, ½ÃÀå ÁøÃâ ±â¾÷ÀÇ °³¿ä µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2011³â 01¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö 144 Pages
The Antiviral Pipeline: HIV, HCV, and Influenza Report
»ùÇÃ
»óǰÄÚµå :145786
HIV, CÇü °£¿°, ÀÎÇ÷翣ÀÚÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ °³¹ß¿¡ ´ëÇÑ Ãֽе¿ÇâÀ» ºÐ¼®Çϰí, ºÐ¾ßº° ÆÄÀÌÇÁ¶óÀÎ(Pipeline)À¸·Î ±â´ëµÇ´Â ¾àÁ¦ °³¿ä, ÇâÈÄ Àü¸Á, Àü¹®°¡ÀÇ ÀÎÅÍºä °á°ú µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2010³â 11¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
RNAi Therapeutics: Second-Generation Candidates Build Momentum Report
»ùÇÃ
»óǰÄÚµå :145784
RNAi Ä¡·áÁ¦ °³¹ß µ¿ÇâÀ» ºÐ¼®Çϰí, RNA °£¼· ¼³°è, Àü´Þ ½Ã½ºÅÛ, ½ÃÀå¿¡ ÁøÃâÇÑ ÁÖ¿ä ±â¾÷ÀÇ °³¿ä, ´ëÇü Á¦¾àȸ»çÀÇ ¿ªÇÒ, ÇâÈÄ Àü¸Á, Àü¹®°¡ÀÇ °ßÇØ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2010³â 10¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö 136 Pages
Next-Generation Sequencing Technologies: Applications and Markets Report
»ùÇÃ
»óǰÄÚµå :129401
Â÷¼¼´ë ½ÃÄö½Ì ±â¼ú(Next-Generation Sequencing Technologies) °³¿ä¿Í ±× ±âÃÊ ¿¬±¸, ÀÀ¿ë ¿¬±¸, ½ÃÀåÀÇ ±Ô¸ð¿Í µ¿Çâ µîÀ» Á¶»ç ºÐ¼®Çϰí, Àü¹®°¡ÀÇ °ßÇØ¸¦ ÇÔ²² ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2010³â 10¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Nuclear Receptors: The Pipeline Outlook
»ùÇÃ
»óǰÄÚµå :129400
ÇÙ ¼ö¿ëü¿¡ °üÇÑ ÀÓ»ó¡¤ÀÓ»ó Àü ´Ü°èÀÇ °³¹ß Ȱµ¿¿¡ ÁÖ¸ñÇÏ¿© Çã°¡ Á¦Ç°ÀÇ ¸ÅÃâ°ú ÇâÈÄ ÀáÀ缺, °ü·Ã ÁúȯÀ¸·ÎÀÇ ÀûÀÀ, ÇâÈÄ Ä¡·áÁ¦ ½ÃÀåÀÇ ¹æÇ⼺ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2010³â 09¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Diabetes Pipeline: Intense Activity to Meet Unmet Need Report
»ùÇÃ
»óǰÄÚµå :129399
¼¼°è ´ç´¢º´ ½ÃÀå ¹× Ãâ½Ã Ä¡·áÁ¦ÀÇ °³¿ä, °³¹ß ÆÄÀÌÇÁ¶óÀÎ(Pipeline) µ¿Çâ, ½ÃÀå ÁøÃâ ±â¾÷ °³¿ä, 2014³â±îÁöÀÇ ¿¹Ãø µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2010³â 09¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö 140 Pages
Therapeutic Protein Production: A Changing Landscape Report
»ùÇÃ
»óǰÄÚµå :125508
µ¿¹°¼¼Æ÷ ¹è¾ç¿¡ °üÇÑ Âù¹Ý¾ç·Ð°ú ´ëüÀû ¼¼Æ÷ÁÙ±â Á¦Á¶ ¹æ¹ý, ¹èÁö·®´ç ´Ü¹éÁú Á¦Á¶·®, Downstream ºÎ¹®ÀÇ ¹®Á¦Á¡, À¯·´ ¹× ¹Ì±¹¿¡¼­ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì(Bioprocessing)¿¡ ´ëÇÑ ¹ý±ÔÁ¦ µ¿Çâ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2010³â 07¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Drug Repositioning: Extracting Added Value from Prior R&D Investments Report
»ùÇÃ
»óǰÄÚµå :125506
µå·° ¸®Æ÷Áö¼Å´×(Drug Repositioning)ÀÇ ±âȸ ¹× ºñÁî´Ï½º Àü·«, ¹ý±ÔÁ¦ ±¸Á¶, È­ÇÕ¹° ¸®Æ÷Áö¼Å´× »ç·Ê¿¬±¸, Áß¿ä ±â¾÷ÀÇ È°µ¿, ÇâÈÄ Àü¸Á µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2010³â 07¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö 126 Pages
Epigenetic Drug & Diagnostic Pipelines: DNA Methylation, HDAC Inhibitors, and Emerging New Targets Report
»ùÇÃ
»óǰÄÚµå :119565
¿¡ÇÇÁ¦³×ƽ(Epigenetic, ÈļºÀ¯ÀüÇÐ)¿¡ ÀÇÇÑ ÀǾàǰ ¹× Áø´Ü¹ýÀÇ °³¹ß µ¿ÇâÀ» Á¶»ç ºÐ¼®Çϰí, ¿¡ÇÇÁ¦³×ƽ°ú ±× ¸ÞÄ¿´ÏÁòÀÇ °³¿ä, ¿¡ÇÇÁ¦³×ƽ ±â¹Ý Ä¡·áÀÇ Ç¥Àû, Áß¿ä ±â¾÷ Ȱµ¿, Á¦Ç° °³¹ß ±â¾÷ÀÇ ºñÁî´Ï½º ¹®Á¦ ¹× °ËÅä »çÇ×, Àü¹®°¡ÀÇ interview µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2010³â 06¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
»ùÇÃ
»óǰÄÚµå :116973
»ý¸í°øÇÐ(Life Sciences) R&D¿¡¼­ÀÇ Å¬¶ó¿ìµå ÄÄÇ»ÆÃ(Cloud Computing) »ç¿ë µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ °³¿ä, ÁøÈ­¿Í ±â¼ú ¹è°æ, »ý¸í°øÇÐ ºÐ¾ß¿¡¼­ÀÇ ÀÀ¿ë, »ç¿ëÀÚÀÇ »ç¿ë µ¿Çâ ¹× ±âÈ£, Àå·¡¼º ºÐ¼® µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2010³â 04¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö 152 pages

»ó±â ÀÚ·á ÀÌ¿ÜÀÇ Insight Pharma Reports ÀÚ·áµµ ÁÖ¹® °¡´ÉÇÏ´Ï ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.